Menu Search
Equities

Immuno-Biological Laboratories Co Ltd

4570:TYO

Immuno-Biological Laboratories Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)445.00
  • Today's Change-14.00 / -3.05%
  • Shares traded150.60k
  • 1 Year change-25.46%
  • Beta0.8867
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Immuno-Biological Laboratories Co Ltd had relatively flat revenues (794.62m to 816.70m), though the company grew net income from a loss of 289.73m to a gain of 186.69m. A reduction in the selling, general and administrative costs as a percentage of sales from 36.33% to 34.41% was a component in the net income growth despite flat revenues.
Gross margin65.48%
Net profit margin26.11%
Operating margin17.87%
Return on assets14.57%
Return on equity18.86%
Return on investment17.43%
More ▼

Cash flow in JPYView more

In 2024, Immuno-Biological Laboratories Co Ltd increased its cash reserves by 20.10%, or 112.97m. The company earned 133.78m from its operations for a Cash Flow Margin of 16.38%. In addition the company generated 992.00k cash from financing while 24.50m was spent on investing.
Cash flow per share5.76
Price/Cash flow per share79.72
Book value per share141.37
Tangible book value per share141.14
More ▼

Balance sheet in JPYView more

Immuno-Biological Laboratories Co Ltd appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio4.75
Quick ratio3.58
Total debt/total equity0.1823
Total debt/total capital0.1542
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.